REPL Company Profile and Key Details
Replimune Group, Inc.
REPL Stock Price Chart
Stock Price Today
Replimune Group, Inc. (REPL) stock surged +9.87%, trading at $13.02 on NASDAQ, up from the previous close of $11.85. The stock opened at $12.08, fluctuating between $11.83 and $13.32 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Company Information
| Employees | 331 |
| Beta | 1.19 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | March |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Replimune Group, Inc. (NASDAQ: REPL) stock price is $13.02 in the last trading session. During the trading session, REPL stock reached the peak price of $13.32 while $11.83 was the lowest point it dropped to. The percentage change in REPL stock occurred in the recent session was 9.87% while the dollar amount for the price change in REPL stock was $1.17.
The NASDAQ listed REPL is part of Biotechnology industry that operates in the broader Healthcare sector. Replimune Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Tanya N. Lewis M.S.
Chief Devel. Operations Officer
Dr. Pamela Esposito Ph.D.
Chief Bus. Officer
Mr. Sushil Patel Ph.D.
Chief Commercial Officer
Dr. Kostas Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Andrew Schwendenman
Chief Accounting Officer
Mr. Christopher Sarchi
Chief Commercial Officer
Mr. Philip Astley-Sparke FSA
Chief Executive Officer & Director
Dr. Sushil Patel Ph.D.
Chief Strategy Officer
Dr. Robert Coffin Ph.D.
Founder, Pres, Chief R&D Officer and Director
Mr. Andrew Schwendenman
Chief Accounting Officer & Treasurer
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.
Chief Medical Officer
Dr. Colin A. Love Ph.D.
Chief Operating Officer
Mr. Philip Astley-Sparke F.S.A., FSA
Chief Executive Officer, Interim Chief Financial Officer & Director
Ms. Jean M. Franchi
Chief Financial Officer, Treasurer, Sec. & Compliance Officer
REPL's closing price is 164.63% higher than its 52-week low of $4.92 where as its distance from 52-week high of $17.00 is -23.41%.
Number of REPL employees currently stands at 331.
Official Website of REPL is: https://www.replimune.com
REPL could be contacted at phone 781 222 9600 and can also be accessed through its website. REPL operates from 500 Unicorn Park Drive, Woburn, MA 01801, United States.
REPL stock volume for the day was 1.45M shares. The average number of REPL shares traded daily for last 3 months was 846.88K.
The market value of REPL currently stands at $980.93M with its latest stock price at $13.02 and 75.34M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com